An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: Proof of principle

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1454-1461

  Spees, William M ^a,b   Gade, Terence P F ^a   Yang, Guangli ^a   Tong, William P ^a,c   Bornmann, William G ^a,c   Gorlick, Richard ^a,d   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; FLUORINE; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; OSTEOSARCOMA; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; TUMOR GROWTH; XENOGRAFT; ANIMAL; BLOOD; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; MALE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLUORINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHOTREXATE; MICE; MICE, NUDE; SARCOMA; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 14644388186     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1439     Document Type: Article

References (47)

1. Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837-44.
2. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5:621-7.
3. Gorlick R, Goker E, Trippet T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
4. Gorlick R, Goker E, Trippet T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-8.
5. Li WW, Lin JT, Schweitzer BI, Tong WP, Niedzwiecki D, Bertino JR. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res 1992;52:3908-13.
6. Hakala MT. On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochim Biophys Acta 1965;102:210-25.
7. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
8. Pignon T, Lacarelle B, Duffaud F, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994;33:420-4.
9. Rousseau A, Sabot C, Delepine N, Debord J, Lachatre G, Marquet P. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet 2002;41:1095-104.
10. 19F magnetic resonance spectra. Mol Cancer Ther 2003;2: 933-9.
11. Presant CA, Wolf W, Waluch V, et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 1994;343:1184-7.
12. 19F magnetic resonance spectroscopy. Clin Cancer Res 1996;2:339-45.
13. Becker ED, Ferreti JA, Gambhir PN. Selection of optimum parameters for pulse Fourier transform nuclear magnetic resonance. Anal Chem 1979;51:1413-20.
14. Evelhoch JL, Crowley MG, Ackerman JJH. Signal-to-noise optimization and observed volume localization with circular surface coils. J Magn Reson 1984;56:110-24.
15. Zakian KL, D'Angelica M, Matei C, et al. A quantitative assessment of liver metabolites during jaundice using three dimensional phosphorus chemical shift imaging. Magn Reson Imaging 2000;18:181-7.
16. Galbán CJ, Spencer RGS. Optimized pulse parameters for reducing quantitation errors due to saturation factor changes in magnetic resonance spectroscopy. J Magn Reson 2002;156:161-70.
17. Li WW, Cordon-Cardo C, Chen Q, Jhanwar SC, Bertino JR. Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines. Int J Cancer 1996;68:514-9.
18. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7:2908-11.
19. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48: 4827-33.
20. Zaharko DS, Dedrick RL, Bischoff KB, Longstreth JA, Oliverio VT. Methotrexate tissue distribution: prediction by a mathematical model. J Natl Cancer Inst 1971;46:775-84.
21. Ballon D, Mahmood U, Jakubowski A, Koutcher JA. Resolution enhanced NMR spectroscopy in biological systems via magnetic susceptibility matched sample immersion chambers. Magn Reson Med 1993;30:754-8.
22. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141-52.
23. Murphy-Boesch J, Jiang H, Stoyanova R, Brown TR. Quantification of phosphorus metabolites from chemical shift imaging spectra with corrections for point spread effects and B1 inhomogeneity. Magn Reson Med 1998;39:429-38.
24. Chu E, Takimoto CH. Antimetabolities. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Vol 1. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1993. p. 358-74.
25. 10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 1979;26:64-72.
26. Cheeseman JR, Trucks GW, Keith TA, Frisch MJ. A comparison of models for calculating nuclear magnetic resonance shielding tensors. J Chem Phys 1996;104:5497-509.
27. Sirotnak FM, Otter GM, Schmid FA. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors. Cancer Res 1993;53:587-91.
28. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-9.
29. Zar JH. Biostatistical analysis. Englewood Cliffs (NJ): Prentice Hall; 1984.
30. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497-507.
31. Salibi N, Brown MA. Clinical MR Spectroscopy: first principles. New York: Wiley-Liss; 1998.
32. McSheehy PM. On the role of MRS in drug development. NMR Biomed 1999;12:402-3.
33. 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 1998;11:380-7.
34. 19F spectroscopy of 5-FU catabolites in human liver. Magn Reson Med 1997;37:321-6.
35. Schlemmer HP, Becker M, Bachert P, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res 1999;59:2363-9.
36. 31P NMR using surface coils. Nature 1980;283:167-70.
37. Nidecker AC, Müller S, Aue WP, et al. Extremity bone tumors: evaluation by P-31 MR spectroscopy. Radiology 1985;157:167-74.
38. Ross B, Helsper JT, Cox J, et al. Osteosarcoma and other neoplasms of bone. Arch Surg 1987;122:1464-9.
39. Fabre G, Goldman ID. Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 1985;45:80-5.
40. 10-methylpteroic acid. J Pharmacol Exp Ther 2000;294:894-901.
41. Chestnut DB, Rusiloski BE, Moore KD, Egolf DA. Use of locally dense basis sets for nuclear magnetic resonance shielding calculations. J Comput Chem 1993;1364-75.
42. 19F chemical shielding in fluorobenzenes implications for chemical shifts in proteins. J Am Chem Soc 1994;7453-4.
43. Breithaupt H, Küenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 1982;66:1733-41.
44. Wolfrom C, Hepp R, Hartmann R, Breithaupt, Henze G. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate therapy. Eur J Clin Pharmacol 1990;39:377-83.
45. 2 to children with acute lymphoblastic leukemia. Med Pediatr Oncol 1990;18: 217-24.
46. 19Fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res 2003;63:7609-12.
47. Gonen O, Murphy-Boesch J, Li CW, Padavic-Shaller K, Negendank WG, Brown TR. Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Magn Reson Med 1997;37:164-9.